Skip to main content
Insights
/ eBooks

Biopharma dealmaking 2024: trends, analysis, forecasts

It's been a difficult year for biopharma dealmaking but there might be light at the end of the tunnel.

Share:

Download the eBook

Business email
First name
Last name
Company name
Job title
Which sector best reflects your role?
By submitting this form, you agree to receive email communications from Inpart as well as the storing and processing of your personal data by Inpart as detailed in the Privacy Statement. You may unsubscribe from these communications at any time.

A bumper year for biopharma?

“This year's review highlighted the genesis of a new upswing in dealmaking fortunes in the industry. DealForma data coupled with the sentiment emerging from a bumper JPM Health Care Conference in San Francisco offer reason to believe that the life sciences is primed for a very good 2024.”

— Gilles Toulemonde, CEO at Inpart

What you will learn in this eBook:

Top 5 biopharma dealmakers by deal count in 2023

Top 5 platform/discovery deals by upfront in 2023

Global IPOs for biopharma in 2023

M&A deals by biopharma in 2023